Monitoring - read more

 

AMS  with its own permanently employed Clinical Research Associates across Europe and its partner CROs, globally, achieves extraordinarily good results in many aspects. This has been confirmed repeatedly by our clients.

AMS  CRAs have a broad range of indication experience with a strong focus in oncology and immunology (among others). Specialized teams operate with specific processes in early development clinical trials or late stage projects, respectively.

AMS  over the last decade repeatedly was the 1st to introduce new monitoring techniques and benefits today from having sound experience in using processes, such as Remote Monitoring, Centralized Monitoring and Risk-based-Monitoring.

AMS  operates a fully validated and easy to use EDC-system with extraordinarily good user acceptance at site level. Additionally, AMS  provides the most modern BYOD ePRO technologies* which have opened new possibilities in data collection, directly derived from patients.


*the fully validated AMS  BYOD-type Patient Reported Outcome solution (AMS -ePRO;) will help to save money and time, e.g. with Patient Diaries and Quality of Life Questionnaires. It significantly reduces the administrative burden in clinical trials.

 

Contact us:

Monitoring

• 2011 – AMS AMNOG Services pioneer • 2013 – AMS-Investigator SELF-TRAINING PORTAL • 2013 – “BEST CRO” by one of ther world’s Top 5 Pharma companies’ CRO Evaluation for AMS – Clinical Operations Services • 2014 – AMS performs Medical App Studies including eCRF-data integration • 2015 – AMS Medical Science is awarded “Provider of the Year, worldwide” the world’s Top 10 Pharma companies • 2015 – AMS develops an E-feasibility tool • 2015 – Innovative Tool for Patient Reported Outcomes: AMS-ePRO (BYOD-type PRO solution) is developed • 2016 – AMS – Regulatory Affairs is nominated on the short-list for TOPRA Award for Regulatory Excellence

News

  • EUnetHTA Open Call for Early Dialogue Requests

    EUnetHTA Open Call for Early Dialogue...

    Informationen
    Artikel vom 09 Juli 2020 News
    EUnetHTA’s Joint Action 3 has been prolonged to May 31, 2021. After a temporary suspension of Early Dialogues (ED) due to the current pandemic situation, ED...
  • EUnetHTA publishes the second iteration of the EUnetHTA Prioritisation List (EPL)

    EUnetHTA publishes the second...

    Informationen
    Artikel vom 01 August 2019 News
    It’s time to get involved: EUnetHTA publishes the second iteration of the EUnetHTA Prioritisation List (EPL) EUnetHTA’s Joint Action 3 will definitely end in...
  • EMA-EUnetHTA Parallel Consultation

    EMA-EUnetHTA Parallel Consultation

    Informationen
    Artikel vom 01 August 2017 News
    Profit from the simultaneous feedback of regulatory and HTA bodies in order to generate your data set in the most efficient way! What is new? EMA and EUnetHTA have...
  • AbbVie TRIUMPH AWARD 2015

    AbbVie TRIUMPH AWARD 2015

    Informationen
    Artikel vom 24 Juni 2016 News
    Um Kooperationen auszuzeichnen und Partner entsprechend zu honorieren, verleiht AbbVie Global jährlich den Preis 'Supplier of the Year'. Kriterien, um für den...
  • AMS electronic Patient Reported Outcomes (AMS-ePRO®)

    AMS electronic Patient Reported...

    Informationen
    Artikel vom 01 Juni 2016 News
    AMS electronic Patient Reported Outcomes (AMS-ePRO®) AMS-ePRO® supports Clinical Research You can now capture your patients data Anytime Anywhere with...